Furthermore, BEX2 overexpression enhances the antiproliferative effect of tamoxifen, suggesting the involvement of the NGF/BEX2/NF-kB pathway in the modulation of the response to the hormonal drug in primary breast cancer. The gene discussed is BEX2; the disease is breast carcinoma.